Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00245102 · ClinicalTrials.gov registry record · Phase 2
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
A Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Stage III Adult Soft Tissue Sarcoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
- 1
- Study location
NCT00245102: Completed Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Stage III Adult Soft Tissue Sarcoma, sponsored by National Cancer Institute (NCI).
NCT00245102 is a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Stage III Adult Soft Tissue Sarcoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 147 participants, above the 75-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (96% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00245102, a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Stage III Adult Soft Tissue Sarcoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well sorafenib works in treating patients with metastatic, locally advanced, or recurrent sarcoma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Primary Outcome
A 5% response rate is considered not promising, a 20% response rate is considered promising. For each stratum, the response rate will be estimated and a confidence interval will be constructed.
Conditions Studied
Interventions
- DRUG sorafenib tosylate
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2005-09 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
What the finished NCT00245102 record still lists
NCT00245102 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, above the 75-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (96% higher).
The record links to 10 conditions, with Recurrent Adult Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which sorafenib tosylate is the first listed.
NCT00245102 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00245102 about?
NCT00245102 is a clinical study titled "Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma". This phase II trial is studying how well sorafenib works in treating patients with metastatic, locally advanced, or recurrent sarcoma. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
What is the current status of trial NCT00245102?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2005-09. Estimated completion is 2011-03.
What conditions does trial NCT00245102 study?
This clinical trial studies the following conditions: Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Ovarian Sarcoma, Recurrent Uterine Sarcoma, Adult Angiosarcoma.
What interventions are being tested in trial NCT00245102?
The interventions under investigation include: sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00245102?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00245102 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00245102's enrollment target sits among peer trials
147 3rd of 11 higher than 9 of 11 other Recurrent Adult Soft Tissue Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Adult Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
COMPLETED · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
COMPLETED · Phase 2
-
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
COMPLETED · Phase 2
-
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia